Massachusetts And Atlanta

PERSEUS Trial Results Demonstrate Positive Safety and Efficacy Outcomes for Boston Scientific's Novel Platinum Chromium TAXUS(R) Element(TM) Stent System

Older News

NATICK, Massachusetts and ATLANTA, Georgia, March 16, 2010 - Boston Scientific Corporation (NYSE: BSX) today announced 12-month results from its PERSEUS clinical program that demonstrated positive safety and efficacy outcomes in workhorse lesions for the platinum chromium TAXUS(R) Element(TM) Paclitaxel-Eluting Stent System compared to the TAXUS(R) Express2(TM) Paclitaxel-Eluting Stent System.

MORE..

Corporate
|
Products
|
About Me
|
Contact
|
Privacy Policy